Heart 2000;83:338-345 ( March )

Basic research

Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries D M Whelan, W J van der Giessen, S C Krabbendam, E A van Vliet, P D Verdouw, P W Serruys, H M M van Beusekom

Department of Cardiology, Thoraxcenter, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands

Correspondence to: Dr van der Giessen email: vandergiessen{at}card.azr.nl

Accepted 19 October 1999

OBJECTIVETo improve the biocompatibility of stents using a phosphorylcholine coated stent as a form of biomimicry.
INTERVENTIONSImplantation of phosphorylcholine coated (n = 20) and non-coated (n = 21) stents was performed in the coronary arteries of 25 pigs. The animals were killed after five days (n = 6), four weeks (n = 7), and 12 weeks (n = 8), and the vessels harvested for histology, scanning electron microscopy, and morphometry.
MAIN OUTCOME MEASURESStent performance was assessed by studying early endothelialisation, neointima formation, and vessel wall reaction to the synthetic coating.
RESULTSStent thrombosis did not occur in either group. Morphometry showed no significant differences between the two study groups at any time point. At five days both the coated and non-coated stents were equally well endothelialised (91% v 92%, respectively). At four and 12 weeks there was no difference in intimal thickness between the coated and non-coated stents. Up to 12 weeks postimplant the phosphorylcholine coating was still discernible in the stent strut voids, and did not appear to elicit an adverse inflammatory response.
CONCLUSIONIn this animal model the phosphorylcholine coating showed excellent blood and tissue compatibility, unlike a number of other polymers tested in a similar setting. Given that the coating was present up to 12 weeks postimplant with no adverse tissue reaction, it may be a potential candidate polymer for local drug delivery.


Keywords: phosphorylcholine; stents; coatings; biocompatible materials

---

© 2000 by Heart
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Silvestri, D., Cristallini, C., Gagliardi, M., Barbani, N., D'Acunto, M., Ciardelli, G., Giusti, P. (2009). Acrylic Copolymers as Candidates for Drug-Eluting Coating of Vascular Stents. J Biomater Appl 24: 353-383 [Abstract]  
• Kim, J. W., Seo, H. S., Park, J. H., Na, J. O., Choi, C. U., Lim, H. E., Kim, E. J., Rha, S.-W., Park, C. G., Oh, D. J. (2009). A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction.. J Am Coll Cardiol 53: 1653-1659 [Abstract] [Full Text]  
• van der Giessen, W. J., Sorop, O., Serruys, P. W., Peters-Krabbendam, I., van Beusekom, H. M.M. (2009). Lowering the Dose of Sirolimus, Released From a Nonpolymeric Hydroxyapatite Coated Coronary Stent, Reduces Signs of Delayed Healing. J Am Coll Cardiol Intv 2: 284-290 [Abstract] [Full Text]  
• Hamilos, M., Sarma, J., Ostojic, M., Cuisset, T., Sarno, G., Melikian, N., Ntalianis, A., Muller, O., Barbato, E., Beleslin, B., Sagic, D., De Bruyne, B., Bartunek, J., Wijns, W. (2008). Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses. Circ Cardiovasc Interv 1: 193-200 [Abstract] [Full Text]  
• Chevalier, B., Di Mario, C., Neumann, F.-J., Ribichini, F., Urban, P., Popma, J. J., Fitzgerald, P. J., Cutlip, D. E., Williams, D. O., Ormiston, J., Grube, E., Whitbourn, R., Schwartz, L. B., for the ZoMaxx I Investigators, (2008). A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus- Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries: The ZoMaxx I Trial. J Am Coll Cardiol Intv 1: 524-532 [Abstract] [Full Text]  
• Fajadet, J., Wijns, W., Laarman, G.-J., Kuck, K.-H., Ormiston, J., Munzel, T., Popma, J. J., Fitzgerald, P. J., Bonan, R., Kuntz, R. E., for the ENDEAVOR II Investigators, (2006). Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial. Circulation 114: 798-806 [Abstract] [Full Text]  
• Anis, R R, Karsch, K R (2006). The future of drug eluting stents. Heart 92: 585-588 [Abstract] [Full Text]  
• Garcia-Touchard, A., Burke, S. E., Toner, J. L., Cromack, K., Schwartz, R. S. (2006). Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 27: 988-993 [Abstract] [Full Text]  
• Lowe, R, Menown, I B A, Nogareda, G, Penn, I M (2005). Coronary stents: in these days of climate change should all stents wear coats?. Heart 91: iii20-iii23 [Full Text]  
• Walter, D. H., Cejna, M., Diaz-Sandoval, L., Willis, S., Kirkwood, L., Stratford, P. W., Tietz, A. B., Kirchmair, R., Silver, M., Curry, C., Wecker, A., Yoon, Y.-S., Heidenreich, R., Hanley, A., Kearney, M., Tio, F. O., Kuenzler, P., Isner, J. M., Losordo, D. W. (2004). Local Gene Transfer of phVEGF-2 Plasmid by Gene-Eluting Stents: An Alternative Strategy for Inhibition of Restenosis. Circulation 110: 36-45 [Abstract] [Full Text]  
• Babapulle, M. N., Eisenberg, M. J. (2002). Coated Stents for the Prevention of Restenosis: Part I. Circulation 106: 2734-2740 [Full Text]  
• Regar, E, Sianos, G, Serruys, P W (2001). Stent development and local drug delivery. Br Med Bull 59: 227-248 [Abstract] [Full Text]  
• Windecker, S., Mayer, I., De Pasquale, G., Maier, W., Dirsch, O., De Groot, P., Wu, Y.-P., Noll, G., Leskosek, B., Meier, B., Hess, O. M. (2001). Stent Coating With Titanium-Nitride-Oxide for Reduction of Neointimal Hyperplasia. Circulation 104: 928-933 [Abstract] [Full Text]